Yesterday's front page article in the Financial Times, "UK ministers call for post-Brexit cooperation with EU on drugs", is a good read, but it also missed some interesting points.
Not least of these is just how much of the European Medicines Agency's (EMA) regulation work is currently undertaken by the UK's Medicines & Healthcare Products Regulatory Agency (MHRA). That, and their lease which needs to be paid out to 2039, is likely to mean a difficult break for the EMA from Britain.
There is no doubt that Brexit is an uncertain time for the Pharma and Life Sciences industry in the UK. However, there are potential silver linings - as discussed in our recent article featured in the Pharma Times.
Two senior UK ministers have warned hardline Brexiters they should be ready to accept some continued regulation from Brussels, writing that Britain’s life sciences sector needs collaboration with the EU’s drug regulator after Brexit. The European Medicines Agency, based in London’s Canary Wharf, currently reviews the safety of all medicines produced in the EU. Each member state also has its own national regulatory agency. But the EU medicines agency will leave London when Britain exits the EU, creating uncertainty about whether the UK will have to develop its own freestanding system for drug approvals.